Form 4: Sage Therapeutics Executive Granted Stock Options and Restricted Stock Units

Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, received stock options and restricted stock units as part of an equity incentive plan.

Summary

• Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, was granted 14,000 restricted stock units (RSUs) and options to purchase 28,000 shares of common stock on January 16, 2025.
• The RSUs vest in equal annual installments over four years, starting January 16, 2026.
• The stock options vest with 7,000 shares vesting on January 16, 2026, and the remaining 21,000 shares vesting in 36 equal monthly installments thereafter.
• The stock options were granted under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options and RSUs aligns Shiferman's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract and retain key talent.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for executives in publicly traded biotech companies.
• Vesting schedules are typically structured to incentivize long-term performance and retention, similar to other companies in the sector.

Stakeholder Impact

• The equity grants may positively impact shareholder value by incentivizing executive performance.
• The grants are part of the executive's compensation package and may impact employee morale.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, executive compensation, insider trading, Form 4, Sage Therapeutics